United Therapeutics Corporation or Sarepta Therapeutics, Inc.: Who Leads in Yearly Revenue?

Biotech Giants' Revenue Race: United vs. Sarepta

__timestampSarepta Therapeutics, Inc.United Therapeutics Corporation
Wednesday, January 1, 201497570001288519000
Thursday, January 1, 201512530001465761000
Friday, January 1, 201654210001598800000
Sunday, January 1, 20171545840001725300000
Monday, January 1, 20183010340001627800000
Tuesday, January 1, 20193808330001448800000
Wednesday, January 1, 20205400990001483300000
Friday, January 1, 20217018870001685500000
Saturday, January 1, 20229330130001936300000
Sunday, January 1, 202312433360002327500000
Loading chart...

Unleashing the power of data

United Therapeutics vs. Sarepta Therapeutics: A Revenue Showdown

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, United Therapeutics Corporation has consistently outperformed Sarepta Therapeutics, Inc. in terms of annual revenue. From 2014 to 2023, United Therapeutics saw a steady increase, culminating in a 2023 revenue of approximately $2.33 billion, marking an 81% growth from 2014. In contrast, Sarepta Therapeutics, while showing impressive growth, reached a 2023 revenue of about $1.24 billion, a staggering increase of over 12,600% from its 2014 figures. This dramatic rise highlights Sarepta's rapid expansion in the biotech sector. However, United Therapeutics' consistent revenue stream underscores its established market presence. As both companies continue to innovate, the revenue race remains a fascinating aspect of their financial narratives.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025